Long Waits Over for New Medications in Pediatric Rheumatology
Post Date: September 13, 2023 | Publish Date:
After overcoming built-in delays in the FDA approval process for pediatric medications, several new therapies are beginning to change outcomes for children with rheumatic diseases.
Hermine Brunner, MD, MSc, MBA, director of the Division of Rheumatology at Cincinnati Children’s, discussed the latest developments in pediatric care on Sept. 9, 2023, in a presentation to an annual meeting of the Congress of Clinical Rheumatology.
Her presentation recapped the recent approvals of belimumab, golimumab, tofacitinib, secukinumab and ustekinumab in children–all of which were approved in the past four years.